The newly identified TP53 mutation in liquid biopsies during ABC treatment was associated with poor prognosis, and the evolutionary pattern of TP53 mutation could potentially serve as a prognostic factor for recurrent BC patients. The gene discussed is TP53; the disease is breast cancer.